electroCore to Participate at Upcoming Investor Conferences
Get Alerts ECOR Hot Sheet
Join SI Premium – FREE
ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be participating at the H.C. Wainwright 24th Global Investment Conference and Ladenburg Thalmann 2022 Healthcare Conference.
H.C. Wainwright 24th Annual Global Investment Conference
Date: Wednesday, September 14, 2022
Time: 12:30 - 1:00 PM EDT
Event: Fireside Chat
Ladenburg Thalmann 2022 Healthcare Conference
Date: Thursday, September 29, 2022
Time: 3:30 - 3:55 PM EDT
Event: Presentation
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
Investors:
Rich Cockrell
CG Capital
404-736-3838
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VEON and JazzWorld Acquire TPL Insurance to Expand Digital Insurance Access Across Pakistan
- Capilea México Releases Overview of Hair Transplant Success Rates and FUE Technology in Mexico
- Edelson Lechtzin LLP Is Investigating Richemont (Compagnie Financière Richemont S.A.) Over Tariff-Driven Price Increases That Were Not Refunded to Consumers After the Supreme Court Struck Down the Ta
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Ladenburg Thalmann Financial Services, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share